TME Pharma

Noxxon Pharma is a clinical-stage biopharmaceutical company with a core focus on improving cancer treatment by targeting the tumor microenvironment. Noxxon Pharma aims to significantly enhance the effectiveness of cancer therapies, including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). Noxxon Pharma's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets, including its leading cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co., Inc./MSD (NYSE: MRK) to study NOX-A12 in combination with KEYTRUDA® (pembrolizumab) for pancreatic and colorectal cancers. Noxxon Pharma’s pipeline also includes NOX-E36, which targets other tumor microenvironment factors involved in cancer metastasis and the immune privilege of tumors.